AntonioJaimeSanchezMDFACP

Clinical Trials

• Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis Start of enrollment: 2013 Jun 01

  Completed

  Phase 2

• Efficacy and Safety Study of Cenicriviroc for the Treatment of Nonalcoholic Steatohepatitis (NASH) in Adult Participants With Liver Fibrosis Start of enrollment: 2014 Sep 18

  Completed

  Phase 2

• Study To Confirm Efficacy and Safety of Terlipressin in Hepatorenal Syndrome (HRS) Type 1 Start of enrollment: 2016 Jul 13

  Completed

  Phase 3

• Volixibat (SHP626) in the Treatment of Adults With Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2016 Oct 24

  Terminated

  Phase 2

• AURORA: A Study for the Efficacy and Safety of Cenicriviroc (CVC) for the Treatment of Liver Fibrosis in Adults With Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2017 Apr 05

  Terminated

  Phase 3

• Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis Start of enrollment: 2017 Feb 13

  Terminated

  Phase 3

• Safety and Efficacy of Selonsertib in Adults With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2017 Jan 30

  Terminated

  Phase 3

• A Study of Glecaprevir (GLE)/Pibrentasvir (PIB) in Treatment-Naive Adults With Chronic Hepatitis C Virus (HCV) Genotype 1-6 Infection and Compensated Cirrhosis Start of enrollment: 2017 Apr 28

  Completed

  Phase 3

• A Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis Start of enrollment: 2017 Dec 27

  Completed

  Phase 2

• A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH Start of enrollment: 2020 Jan 27

  Terminated

  Phase 2

• A Study of MK-3655 in Individuals With Pre-cirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-3655-001) Start of enrollment: 2020 Nov 11

  Terminated

  Phase 2

• A Study to Test Safety and Efficacy of BI456906 in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3) Start of enrollment: 2021 Apr 27

  Completed

  Phase 2

• Phase 2b Study of GSK4532990 in Adults With NASH Start of enrollment: 2023 Jan 02

  Recruiting

  Phase 2

• A Clinical Study of Efinopegdutide in Participants With Precirrhotic Nonalcoholic Steatohepatitis (NASH) (MK-6024-013) Start of enrollment: 2023 Jun 23

  Recruiting

  Phase 2

• A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) Start of enrollment: 2021 Aug 19

  Recruiting

  Phase 3

• Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis Start of enrollment: 2022 Apr 01

  Active, not recruiting

  Phase 2, Phase 3

• Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis Start of enrollment: 2022 Oct 06

  Active, not recruiting

  Phase 2

• An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease Start of enrollment: 2023 Aug 08

  Enrolling by invitation

  Phase 3

• Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) Start of enrollment: 2021 Aug 09

  Active, not recruiting

  Phase 2

• A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis Start of enrollment: 2021 Sep 22

  Recruiting

  Phase 2

• Study to Evaluate Adverse Events and Change in Disease Activity in Adult and Adolescent Participants With Acute Hepatitis C Virus (HCV) Infection on Treatment With Oral Tablets of Glecaprevir (GLE)/Pibrentasvir (PIB) Start of enrollment: 2021 Aug 24

  Active, not recruiting

  Phase 3

• Join now to see all